Capex Push Cuts Across Banking, Industrials, Health and Retail
Eight companies disclosed economic commentary this week across five industries, and seven of them, from banking to biotech to storage, pointed to capital deployment as the throughline.
Coverage: 7 of 8 companies in this theme (FHB, TCBK, ARMP, BW, PLUG, PSA, REZI) — a sample, not the full set.
Eight companies across five industries disclosed economic commentary this week, and seven of them landed on the same throughline: capital deployment. Whatever else diverged in their businesses, the message from banking, industrials, healthcare, real estate and retail was that firms are still directing cash toward expansion, buybacks and project spending.
In banking, the growth story is geographic. First Hawaiian (FHB) and TriCo Bancshares (TCBK) both framed California as the target market this week, describing mainland expansion as a continuation of First Hawaiian's decades-long presence there and pointing to a partnership built on that history. The nearly identical language coming out of both banks suggests a shared expansion rationale is playing out across two separate disclosures rather than two unrelated stories.
Industrial names split between spending on growth and returning capital, and one of them did both at once. Babcock & Wilcox Enterprises (BW), based in Akron, Ohio, said repurchasing shares when they represent "compelling value" is an "opportunistic use of" its financial position, and paired that buyback stance with "continued investment to support" its growth and demand. Plug Power (PLUG) pointed to project-level economics, flagging a contingent earnout of up to $26.5 million tied to the electrical load capacity ultimately established for a project; the payout scales directly with how much infrastructure actually gets built.
Healthcare and real estate showed the same instinct applied to very different balance sheets. Armata Pharmaceuticals (ARMP) linked its investment posture to clinical development, describing a strategy that "establishes a pathway for potential future expansion of AP-SA02 into the pediatric population while prioritizing patient safety". For a clinical-stage biotech, that capex line funds the development pathway itself. Public Storage (PSA) disclosed continuing investment-banking and advisory work with its underwriters, who have "received customary fees" for services performed "from time to time", a sign that deal-related capital-markets activity remains a live part of its financial operations.
Resideo Technologies (REZI) put the clearest number on the theme, showing consolidated capex climbing from $105 million in 2023 to $121 million in the trailing twelve months through the first quarter of 2024, even after stripping out ADI-related capex under its Form 10 reporting. That trajectory gives the week's broader capex narrative an actual figure to anchor to, rather than leaving it as language alone.
Taken together, the cohort's capital-allocation commentary spans mainland bank expansion, pediatric drug development, storage-sector advisory fees and industrial project financing. Seven companies out of eight, across five unrelated industries, chose to talk about where their money is going this week, which says more about the current posture of the corporate economy than any single data point could.